press statements – en – old

October 2023 – Naomi Dirckx’s presentation about “The longevity transporter SLC13A5 as a promising target for the prevention of age-related bone loss“ at the ASBMR was selected as meeting highlight

Eternygen's collaborator Naomi Dirckx from University of Maryland, Baltimore presents most recent data about “The longevity transporter SLC13A5 as a ...

September 2023 – Eternygen founder Prof. Birkenfeld published exciting work about pre-diabetes in The Lancet Diabetes & Endocrinology

Eternygen founder Prof. Birkenfeld published exciting work about pre-diabetes in The Lancet Diabetes & Endocrinology. Find the article here. Find ...

August 2023 – Eternygen published new data: citrate transporter INDY/NaCT/SLC13A5 as a therapeutic target for kidney diseases

In collaboration with Dipender Gill and Stephen Burgess, we've identified a noteworthy new connection between hepatic INDY/SLC13A5 and kidney function. This ...

August 2023 – Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep

Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep ...

July 2023 – Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity

Eternygen´s founder Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity. (in German) Find the video here ...

March 2023 – Eternygen at BioEuropeSpring conference

Meet Eternygen at BioEuropeSpring conference in Basel from 20-22 March 2023 More information here ...

October 2022 – Eternygen at BioEurope conference

Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022 More information here ...

September 2022 – Grit Zahn presents at TESS Research Foundation’s International Research Conference and biotx.ai in September

Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation's International Research Conference in Vienna ...

August 2022 – Eternygen at the “Aging research and drug discovery meeting” in Copenhagen

Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from August 28th to 1 September ...

August 2022 – Eternygen published new paper on SLC13A5 inhibitors

Eternygen published new paper on SLC13A5 inhibitors titled: “A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis ...